Cargando…
Critical evaluation of latanoprostene bunod in the treatment of glaucoma
Latanoprostene bunod (LBN) is a novel nitric oxide-donating prostaglandin F(2α) receptor agonist in clinical development for intraocular pressure lowering in open-angle glaucoma and ocular hypertension. Currently in Phase III clinical trials in the USA, European Union, and Japan, LBN has demonstrate...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5079698/ https://www.ncbi.nlm.nih.gov/pubmed/27799730 http://dx.doi.org/10.2147/OPTH.S103985 |